On Nov. 9, an FDA committee voted 8-5 against Veru Pharma’s sabizabulin, deciding the risks outweigh the potential benefits, according to a news release from the drugmaker. Veru submitted an emergency use authorization application in June for sabizabulin to be intended to treat hospitalized moderate to severe COVID-19 patients who are at high risk for acute respiratory distress syndrome.
The FDA will make a final decision based on the panel’s discussion.
On Nov. 10, the FDA authorized Swedish Orphan Biovitrum’s Kineret (anakinra) for emergency use to treat hospitalized COVID-19 adults with pneumonia who require supplemental oxygen and are at risk of progressing to severe respiratory failure. Sobi, which is based in Stockholm, said in a news release the medication’s authorization was an “important milestone.”
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
